Ironwood Pharmaceuticals, Inc. logo

IRWD

Ironwood Pharmaceuticals, Inc.

$12

Earnings Summary

Revenue
$69.16Mn
Net Profits
$-43.14Mn
Net Profit Margins
-62.39%

Highlights

Revenue:

Ironwood Pharmaceuticals, Inc.’s revenue jumped 32.57% since last year same period to $69.16Mn in the Q1 2018. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated -26.59% fall in its revenue since last 3-months.

Net Profits:

Ironwood Pharmaceuticals, Inc.’s net profit jumped 17.82% since last year same period to $-43.14Mn in the Q1 2018. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated -457% fall in its net profits since last 3-months.

Net Profit Margins:

Ironwood Pharmaceuticals, Inc.’s net profit margin jumped 38.01% since last year same period to -62.39% in the Q1 2018. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated -586.34% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ironwood Pharmaceuticals, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
0.38
EPS Estimate Current Year
0.38

Highlights

EPS Estimate Current Quarter:

Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.38 - a 18.95% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 0.38.

Key Ratios

Key ratios of the Ironwood Pharmaceuticals, Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
0.21
Return on Assets (ROA)
0.14
Return on Equity (ROE)
0.29

Highlights

Earning Per Share (EPS):

Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) fell -91.21% since last year same period to 0.21 in the Q2 2022. This indicates that the Ironwood Pharmaceuticals, Inc. has generated -91.21% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ironwood Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.14.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ironwood Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.29.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-04
0.33
0.21
-35.96%
2022-05-05
0.32
0.21
-33.33%

Company Information

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

Organisation
Ironwood Pharmaceuticals, Inc.
Headquarters
100 Summer Street, Boston, MA, United States, 02110
Employees
219
Industry
Health Technology
CEO
Mark Mallon

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*